The Jenex Corporation issues shares for debt

    BURLINGTON, ON, March 9 /CNW/ - The Jenex Corporation ("Jenex" or the
"Corporation") (TSX Venture Exchange: JEN, Frankfurt: JNX) announced today
they will issue 148,148 common shares at a deemed price of 27 cents per common
share as consideration for the settlement of $40,000 in trade payables owed to
a consultant of the corporation. The proposed transaction is arm's length. The
transaction is subject to TSX Venture Exchange approval and the shares will be
subject to a four-month hold period from the date of issue.

    About The Jenex Corporation

    The Jenex Corporation owns a patented Thermal Therapy technology. The
first device developed from this technology is the Therapik(R) product, for
relief of pain and itch caused by insect stings and bites. Therapik(R) has
been approved as a Class II medical device in Canada (TPD) and the United
States (FDA), and has received CE approval in Europe. The second device,
interceptCS is the first product clinically proven and approved (TPD) to
prevent cold sores. interceptCS is available exclusively in Canada at Shoppers
Drug Mart/Pharmaprix. More information about the Corporation can be found at & www.

                         "Prevention is the Solution"

     The TSX Venture Exchange Inc. has not reviewed and does not accept
           responsibility for the accuracy or the contents of this
                               press release.

    %SEDAR: 00016201E

For further information:

For further information: Direct Inquiries to: The Jenex Corporation, 207
- 940 Sheldon Court, Burlington, Ontario, L7L 5K6, Michael A. Jenkins,
Telephone: (905) 632-3830, Facsimile: (905) 632-3774, Email:, Website:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890